Stock LUMO LUMOS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Delayed Nasdaq
Other stock markets
 09:05:09 13/05/2024 pm IST 		5-day change 1st Jan Change
2.886 USD -0.50% Intraday chart for Lumos Pharma, Inc. -3.82% -9.26%
07/03 Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
07/03 Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
GL
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
GL
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
GL
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024
Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M
MT
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
GL
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
GL
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
AQ
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
GL
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
AQ
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
GL
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
AQ
Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer
CI
Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating
MT
Transcript : Lumos Pharma, Inc. - Special Call
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
GL
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
AQ
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
GL
North American Morning Briefing : Stock Futures -2-
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LUMO Stock
  4. News Lumos Pharma, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW